Alpha-Emitters for Immuno-Therapy: A Review of Recent Developments from Chemistry to Clinics

被引:0
|
作者
Huclier-Markai, Sandrine [1 ]
Alliot, Cyrille [2 ,3 ]
Varmenot, Nicolas [2 ,4 ]
Cutler, Cathy S. [5 ]
Barbet, Jacques [2 ,3 ]
机构
[1] Univ Nantes, Ecole Mines Nantes, Lab Subatech, UMR 6457,CNRS IN2P3, F-44307 Nantes 3, France
[2] ARRONAX GIP, F-44817 Nantes, France
[3] Univ Nantes, CRCNA Inserm, U892, F-44007 Nantes 1, France
[4] Inst Cancerol lOuest Rene Gauducheau, F-44805 St Herblain, France
[5] Univ Missouri, Res Reactor Ctr, Columbia, MO 65211 USA
关键词
Pb-212; Bi-212; Bi-213; At-211; Ra-223; Ac-225; VASCULAR TARGETED RADIOIMMUNOTHERAPY; PARTICLE-EMITTING RADIONUCLIDES; IN-VIVO STABILITY; MONOCLONAL-ANTIBODY; BETA-DECAY; PRETARGETED RADIOIMMUNOTHERAPY; ENDORADIOTHERAPEUTIC DRUG; GENERATOR; BI-213; ASTATINE;
D O I
暂无
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Alpha-particles are of considerable growing interest for Targeted Alpha Therapy (TAT). TAT gains more attention as new targets, chemical labeling techniques and alpha-particle emitters are developed but translation of TAT into the clinic has been slow, in part because of the limited availability and the short physical half-lives of some of the available alpha-particle emitters. This article is an up-to-date overview of the literature concerning alpha-emitters used for of cancer. It briefly describes the nuclear characteristics, the production parameters (targets, extraction and purification), the complexation properties of these radionuclides to chelates and biological vectors and finally draws-upon the preclinical and clinical studies that have been performed over the past two decades. Radiobiology and dosimetry aspects are also presented in this paper.
引用
收藏
页码:2642 / 2654
页数:13
相关论文
共 50 条
  • [1] Advancements in cancer therapy with alpha-emitters: A review
    Imam, SK
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2001, 51 (01): : 271 - 278
  • [2] Cancer Therapy with Alpha-Emitters Labeled Peptides
    Dadachova, Ekaterina
    SEMINARS IN NUCLEAR MEDICINE, 2010, 40 (03) : 204 - 208
  • [3] Alpha-Emitters and Targeted Alpha Therapy in Oncology: from Basic Science to Clinical Investigations
    Mehran Makvandi
    Edouard Dupis
    Jonathan W. Engle
    F. Meiring Nortier
    Michael E. Fassbender
    Sam Simon
    Eva R. Birnbaum
    Robert W. Atcher
    Kevin D. John
    Olivier Rixe
    Jeffrey P. Norenberg
    Targeted Oncology, 2018, 13 : 189 - 203
  • [4] Alpha-Emitters and Targeted Alpha Therapy in Oncology: from Basic Science to Clinical Investigations
    Makvandi, Mehran
    Dupis, Edouard
    Engle, Jonathan W.
    Nortier, F. Meiring
    Fassbender, Michael E.
    Simon, Sam
    Birnbaum, Eva R.
    Atcher, Robert W.
    John, Kevin D.
    Rixe, Olivier
    Norenberg, Jeffrey P.
    TARGETED ONCOLOGY, 2018, 13 (02) : 189 - 203
  • [5] ALPHA-EMITTERS IN THE REGION FROM CE TO OS
    RURARZ, E
    ACTA PHYSICA POLONICA B, 1983, 14 (12): : 917 - 951
  • [6] A Comprehensive Review of Diffusing Alpha-Emitters Radiation Therapy (DaRT): From Dosimetry to Its Biological Effectiveness
    Kim, Seohan
    Sung, Wonmo
    JOURNAL OF RADIATION PROTECTION AND RESEARCH, 2024, 49 (03): : 102 - 113
  • [7] APPLICATION OF A NOVEL MONTE CARLO BASED METHOD TO DETERMINE THE EMBEDDED DISTRIBUTIONS OF ALPHA-EMITTERS FROM THEIR MEASURED ALPHA SPECTRA IN DIFFUSING ALPHA-EMITTERS RADIATION THERAPY (DART)
    Mondor, Julien
    Carrier, Jean-Francois
    Kamio, Yuji
    RADIOTHERAPY AND ONCOLOGY, 2023, 186 : S85 - S86
  • [8] Simulation of particle release for Diffusing Alpha-Emitters Radiation Therapy
    Fedorchenko, Dmytro
    Alani, Shlomi
    APPLIED RADIATION AND ISOTOPES, 2023, 197
  • [9] Approximate modeling for dose calculations in Diffusing Alpha-emitters Radiation Therapy
    Arazi, L.
    Dumancic, M.
    Keisari, Y.
    Kelson, I.
    RADIOTHERAPY AND ONCOLOGY, 2020, 152 : S110 - S110